Furthermore, the loss of Sestrin2 increased hepatic vulnerability to cholestatic liver injury, as assessed by serum ALT levels, fibrosis, and apoptosis (Fig. 8), suggesting that Sestrin2 is involved in protecting against cholestatic liver disease. This evidence concerns the gene GPT and Cholestatic liver disease.